Kantaro is a joint venture between Mount Sinai Health System and RenalytixAI.
As part of the agreement, Atrys Health will distribute Kantaro’s quantitative SARS-CoV-2 IgG antibody test kits in selected South American and European territories, including Portugal, Spain, Colombia, Peru, Brazil, and Chile.
Kantaro’s COVID-SeroKlir and COVID-SeroIndex are enzyme-linked immunosorbent assays (ELISA). They are CE-marked for identifying the presence and precise level of neutralising IgG antibodies.
The antibodies are produced in the body as part of its immune response to Covid-19 virus exposure.
Kantaro chief commercial officer Sara Barrington said: “Atrys Health is the latest in a growing list of high-quality distribution partners. This agreement represents another critical step forward in bringing the Kantaro quantitative antibody tests to doctors, patients, and researchers in regions affected by Covid-19.
“We believe this type of antibody testing is increasingly relevant at this point in the pandemic to provide peace of mind and answer important questions about vaccine response, longevity, and immunity.”
According to the company, its quantitative SARS-CoV-2 IgG antibody tests have shown a 97.8% sensitivity and 99.6% specificity for detecting Covid-19 IgG antibodies.
The results for the tests, which do not require proprietary equipment, are obtained from a two-step process that uses two virus antigens, namely, the receptor-binding domain (RBD) and the full-length spike protein.
Commenting on the development, Atrys Health CEO Isabel Lozano said: “Our partnership with Kantaro diversifies and widens our portfolio of diagnostics at the forefront of innovation.
“We humbly embrace the opportunity to make the Kantaro quantitative antibody tests available to our customers in Europe and South America and be part of the global effort to increase testing and begin to recover from the Covid-19 pandemic.”
In May last year, Bio-Techne partnered with Kantaro to deliver Covid-19 antibody test kits.